Jump to content

Justin Stebbing: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
changing {{promotional tone}} to {{autobiography}}, having taken a closer look at the history; reinstating and updating some material deleted by the subject of the article
m updates to board positions and other minor changes
Line 4: Line 4:
'''Justin Stebbing''' is a British [[oncology]] doctor, [[cancer research]]er and academic journal editor. He is a Professor of Biomedical Sciences at [[Anglia Ruskin University]]<ref>{{Cite web |title=Professor Justin Stebbing - ARU |url=https://aru.ac.uk/people/justin-stebbing |access-date=2022-11-30 |website=aru.ac.uk}}</ref> and practices with the [[Private healthcare in the United Kingdom|private sector]] Phoenix Hospital Group in London to provide medical services to patients for the management of cancer, in person and remotely.<ref>{{Cite web |title=Professor Justin Stebbing |url=https://www.phoenixhospitalgroup.com/our-specialists/prof-justin-stebbing/ |access-date=2022-10-29 |website=Phoenix Hospital Group }}</ref>
'''Justin Stebbing''' is a British [[oncology]] doctor, [[cancer research]]er and academic journal editor. He is a Professor of Biomedical Sciences at [[Anglia Ruskin University]]<ref>{{Cite web |title=Professor Justin Stebbing - ARU |url=https://aru.ac.uk/people/justin-stebbing |access-date=2022-11-30 |website=aru.ac.uk}}</ref> and practices with the [[Private healthcare in the United Kingdom|private sector]] Phoenix Hospital Group in London to provide medical services to patients for the management of cancer, in person and remotely.<ref>{{Cite web |title=Professor Justin Stebbing |url=https://www.phoenixhospitalgroup.com/our-specialists/prof-justin-stebbing/ |access-date=2022-10-29 |website=Phoenix Hospital Group }}</ref>


He specialises in a range of solid malignancies (breast, GI, lung, others) including difficult cases with few conventional options and has published over 700 papers, the majority regarding new therapeutic and translational approaches including use of [[Immunotherapy|immunotherapies]] in clinical trials.{{citation needed|date=May 2024}}
He specialises in a range of solid malignancies (breast, GI, lung, others) including difficult cases with few conventional options and has published over 700 papers, the majority regarding new therapeutic and translational approaches including use of [[Immunotherapy|immunotherapies]] in clinical trials.<ref>{{Cite web |last=Stebbing |first=Justin |date=2024-05-16 |title=Unlocking the body’s defences: understanding immunotherapy |url=http://theconversation.com/unlocking-the-bodys-defences-understanding-immunotherapy-226858 |access-date=2024-05-18 |website=The Conversation |language=en-US}}</ref>


Stebbing is Editor-in-Chief of the journal ''[[Oncogene (journal)|Oncogene]]''.<ref>{{Cite web |title=About the Editors {{!}} Oncogene |url=https://www.nature.com/onc/editors |access-date=2022-10-29 |website=www.nature.com |language=en}}</ref> He is also a [[visiting Professor]] of Cancer Medicine and Oncology at [[Imperial College London|Imperial College]], London <ref>{{Cite web |title=Home - Professor Justin Stebbing |url=https://www.imperial.ac.uk/people/j.stebbing |access-date=2022-10-29 |website=www.imperial.ac.uk}}</ref>
He is Editor-in-Chief of the journal ''[[Oncogene (journal)|Oncogene]]''.<ref>{{Cite web |title=About the Editors {{!}} Oncogene |url=https://www.nature.com/onc/editors |access-date=2022-10-29 |website=www.nature.com |language=en}}</ref> He is also a [[visiting Professor]] of Cancer Medicine and Oncology at [[Imperial College London|Imperial College]], London <ref>{{Cite web |title=Home - Professor Justin Stebbing |url=https://www.imperial.ac.uk/people/j.stebbing |access-date=2022-10-29 |website=www.imperial.ac.uk}}</ref>


== Early life and education ==
== Early life and education ==
Stebbing graduated with a first class degree from [[Trinity College, Oxford]]. After completion of junior doctor positions in Oxford, he trained on the residency programme at [[Johns Hopkins Hospital|The Johns Hopkins Hospital]] on the Longcope team in the US, returning to London to continue his career in oncology at [[The Royal Marsden NHS Foundation Trust|The Royal Marsden]] and then [[St Bartholomew's Hospital|St Bartholomew's Hospitals]]. His original PhD research investigated the interplay between the immune system and cancer including the role of viruses here.<ref>{{Cite journal |last1=Stebbing |first1=Justin |last2=Gazzard |first2=Brian |last3=Douek |first3=Daniel C. |date=2004-04-29 |title=Where Does HIV Live? |url=http://www.nejm.org/doi/abs/10.1056/NEJMra032395 |journal=New England Journal of Medicine |language=en |volume=350 |issue=18 |pages=1872–1880 |doi=10.1056/NEJMra032395 |pmid=15115833 |issn=0028-4793}}</ref><ref>{{Cite web |title=Redirecting |url=https://linkinghub.elsevier.com/retrieve/pii/S1470204503011422 |access-date=2024-01-07 |website=linkinghub.elsevier.com}}</ref> In 2007 he was appointed a senior lecturer, and then in 2009 a full professor, at [[Imperial College London]].<ref name="imperial stebbing">{{Cite web |title=PWP Messages |url=https://www.imperial.ac.uk/people/j.stebbing}}</ref> In 2011, the [[National Institute for Health and Care Research]] ([[National Institute for Health and Care Research|NIHR]]) awarded Justin Stebbing its first Translational Professorship in Oncology, working on overcoming treatment resistance and new targeted precision medicine approaches.<ref>{{Cite web |title=Current NIHR Research Professors |url=https://www.nihr.ac.uk/documents/current-nihr-research-professors/21758 |access-date=2024-01-07 |website=www.nihr.ac.uk |language=EN}}</ref>
He graduated with a first class degree from [[Trinity College, Oxford]]. After completion of junior doctor positions in Oxford, he trained on the residency programme at [[Johns Hopkins Hospital|The Johns Hopkins Hospital]] on the Longcope team in the US, returning to London to continue his career in oncology at [[The Royal Marsden NHS Foundation Trust|The Royal Marsden]] and then [[St Bartholomew's Hospital|St Bartholomew's Hospitals]]. His original PhD research investigated the interplay between the immune system and cancer including the role of viruses here.<ref>{{Cite journal |last1=Stebbing |first1=Justin |last2=Gazzard |first2=Brian |last3=Douek |first3=Daniel C. |date=2004-04-29 |title=Where Does HIV Live? |url=http://www.nejm.org/doi/abs/10.1056/NEJMra032395 |journal=New England Journal of Medicine |language=en |volume=350 |issue=18 |pages=1872–1880 |doi=10.1056/NEJMra032395 |pmid=15115833 |issn=0028-4793}}</ref><ref>{{Cite web |title=Redirecting |url=https://linkinghub.elsevier.com/retrieve/pii/S1470204503011422 |access-date=2024-01-07 |website=linkinghub.elsevier.com}}</ref> In 2007 he was appointed a senior lecturer, and then in 2009 a full professor, at [[Imperial College London]].<ref name="imperial stebbing">{{Cite web |title=PWP Messages |url=https://www.imperial.ac.uk/people/j.stebbing}}</ref> In 2011, the [[National Institute for Health and Care Research]] ([[National Institute for Health and Care Research|NIHR]]) awarded Justin Stebbing its first Translational Professorship in Oncology, working on overcoming treatment resistance and new targeted precision medicine approaches.<ref>{{Cite web |title=Current NIHR Research Professors |url=https://www.nihr.ac.uk/documents/current-nihr-research-professors/21758 |access-date=2024-01-07 |website=www.nihr.ac.uk |language=EN}}</ref>


== Cancer research ==
== Cancer research ==
Stebbing has published over 700 peer-reviewed papers in academic journals<ref>{{Cite web |title=stebbing j - Search Results - PubMed |url=https://pubmed.ncbi.nlm.nih.gov/?term=stebbing+j |access-date=2024-01-07 |website=PubMed |language=en}}</ref> and has an [[h-index]] of 89 according to [[Google Scholar]].<ref>{{Cite web |title=Justin Stebbing |url=https://scholar.google.com/citations?user=zYQDvoIAAAAJ&hl=en |access-date=2024-01-07 |website=scholar.google.com}}</ref> He is Editor-in-Chief of the journal [[Oncogene (journal)|Oncogene]]<ref>{{cite web |title=About the Editors |url=https://www.nature.com/onc/editors |website=Oncogene }}</ref> a Fellow of the [[Royal College of Physicians]]<ref>{{Cite web |title=Home - Professor Justin Stebbing |url=https://www.imperial.ac.uk/people/j.stebbing |access-date=2024-01-07 |website=www.imperial.ac.uk}}</ref> the [[American Society for Clinical Investigation]]<ref>{{Cite web|url=https://the-asci.org/controllers/asci/AsciProfileController.php?pid=501408|title = The American Society for Clinical Investigation}}</ref> and the [[Royal College of Pathologists]].<ref>{{Cite web |title=Honours and Memberships - Professor Justin Stebbing |url=https://www.imperial.ac.uk/people/j.stebbing/honours-and-memberships.html |access-date=2024-01-07 |website=www.imperial.ac.uk}}</ref> The charity Action Against Cancer was set up to support Justin's work which concentrates on drug development and has the ambitious goal of developing cures.<ref>{{Cite web|url=https://www.aacancer.org/|title=Home &#124; Action Against Cancer|website=www.aacancer.org|accessdate=28 March 2023}}</ref> In cancer, some of his most cited papers include the discovery of the role of the oncogene LMTK3 across malignancies, the network of microRNAs induced by the estrogen receptor, and extensive work on HIV and AIDS cancers.<ref>{{cite journal |last1=Giamas |first1=Georgios |last2=Filipović |first2=Aleksandra |last3=Jacob |first3=Jimmy |last4=Messier |first4=Walter |last5=Zhang |first5=Hua |last6=Yang |first6=Dongyun |last7=Zhang |first7=Wu |last8=Shifa |first8=Belul Assefa |last9=Photiou |first9=Andrew |last10=Tralau-Stewart |first10=Cathy |last11=Castellano |first11=Leandro |last12=Green |first12=Andrew R. |last13=Coombes |first13=R. Charles |last14=Ellis |first14=Ian O. |last15=Ali |first15=Simak |last16=Lenz |first16=Heinz-Josef |last17=Stebbing |first17=Justin |title=Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer |journal=Nature Medicine |date=June 2011 |volume=17 |issue=6 |pages=715–719 |doi=10.1038/nm.2351 |pmid=21602804 |s2cid=5279914 }}{{psc|date=January 2022}}</ref><ref>{{cite journal |last1=Castellano |first1=Leandro |last2=Giamas |first2=Georgios |last3=Jacob |first3=Jimmy |last4=Coombes |first4=R. Charles |last5=Lucchesi |first5=Walter |last6=Thiruchelvam |first6=Paul |last7=Barton |first7=Geraint |last8=Jiao |first8=Long R. |last9=Wait |first9=Robin |last10=Waxman |first10=Jonathan |last11=Hannon |first11=Gregory J. |last12=Stebbing |first12=Justin |title=The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response |journal=Proceedings of the National Academy of Sciences |date=21 August 2009 |volume=106 |issue=37 |pages=15732–15737 |doi=10.1073/pnas.0906947106 |pmid=19706389 |pmc=2747188 |bibcode=2009PNAS..10615732C |doi-access=free }}{{psc|date=January 2022}}</ref><ref>{{cite journal |last1=Bower |first1=M. |last2=Nelson |first2=M. |last3=Young |first3=A.M. |last4=Thirlwell |first4=C. |last5=Newsom-Davis |first5=T. |last6=Mandalia |first6=S. |last7=Dhillon |first7=T. |last8=Holmes |first8=P. |last9=Gazzard |first9=B.G. |last10=Stebbing |first10=J. |title=Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma |journal=Journal of Clinical Oncology |date=1 August 2005 |volume=23 |issue=22 |pages=5224–5228 |doi=10.1200/JCO.2005.14.597 |pmid=16051964 |doi-access=free }}{{psc|date=January 2022}}</ref><ref>{{cite journal |last1=Stebbing |first1=Justin |last2=Gazzard |first2=Brian |last3=Douek |first3=Daniel C. |title=Where Does HIV Live? |journal=New England Journal of Medicine |date=29 April 2004 |volume=350 |issue=18 |pages=1872–1880 |doi=10.1056/NEJMra032395 |pmid=15115833 }}{{psc|date=January 2022}}</ref> He has undertaken extensive work on [[Biosimilar|biosimilars]],<ref>{{Cite web |title=Redirecting |url=https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(17)30434-5 |access-date=2024-01-07 |website=linkinghub.elsevier.com}}</ref> cheaper versions of expensive biologic drugs designed to democratise access to these around the world, now with long term outcomes data.<ref>{{Cite journal |last1=Stebbing |first1=Justin |last2=Baranau |first2=Yauheni |last3=Baryash |first3=Valery |last4=Moiseyenko |first4=Vladimir |last5=Boliukh |first5=Dmytro |last6=Antone |first6=Nicoleta |last7=Manikhas |first7=Alexey |last8=Chornobai |first8=Anatolii |last9=Park |first9=Taehong |last10=Baek |first10=Eric Hyungseok |last11=Lee |first11=Jaeyong |last12=Choi |first12=Jiin |last13=Kim |first13=Nahyun |last14=Ahn |first14=Keumyoung |last15=Lee |first15=Sang Joon |date=2023 |title=Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial |journal=Biodrugs |volume=37 |issue=3 |pages=433–440 |doi=10.1007/s40259-023-00582-w |issn=1173-8804 |pmid=36881323|pmc=10195725 }}</ref>
Stebbing has published over 700 peer-reviewed papers in academic journals<ref>{{Cite web |title=stebbing j - Search Results - PubMed |url=https://pubmed.ncbi.nlm.nih.gov/?term=stebbing+j |access-date=2024-01-07 |website=PubMed |language=en}}</ref> and has an [[h-index]] of 89 according to [[Google Scholar]].<ref>{{Cite web |title=Justin Stebbing |url=https://scholar.google.com/citations?user=zYQDvoIAAAAJ&hl=en |access-date=2024-01-07 |website=scholar.google.com}}</ref> He is Editor-in-Chief of the journal [[Oncogene (journal)|Oncogene]]<ref>{{cite web |title=About the Editors |url=https://www.nature.com/onc/editors |website=Oncogene }}</ref> a Fellow of the [[Royal College of Physicians]]<ref>{{Cite web |title=Home - Professor Justin Stebbing |url=https://www.imperial.ac.uk/people/j.stebbing |access-date=2024-01-07 |website=www.imperial.ac.uk}}</ref> the [[American Society for Clinical Investigation]]<ref>{{Cite web|url=https://the-asci.org/controllers/asci/AsciProfileController.php?pid=501408|title = The American Society for Clinical Investigation}}</ref> and the [[Royal College of Pathologists]].<ref>{{Cite web |title=Honours and Memberships - Professor Justin Stebbing |url=https://www.imperial.ac.uk/people/j.stebbing/honours-and-memberships.html |access-date=2024-01-07 |website=www.imperial.ac.uk}}</ref> The charity Action Against Cancer was set up to support Justin's work which concentrates on drug development and has the ambitious goal of developing cures.<ref>{{Cite web|url=https://www.aacancer.org/|title=Home &#124; Action Against Cancer|website=www.aacancer.org|accessdate=28 March 2023}}</ref> In cancer, some of his most cited papers include the discovery of the role of the oncogene LMTK3 across malignancies, the network of microRNAs induced by the estrogen receptor, and extensive work on HIV and AIDS cancers.<ref>{{cite journal |last1=Giamas |first1=Georgios |last2=Filipović |first2=Aleksandra |last3=Jacob |first3=Jimmy |last4=Messier |first4=Walter |last5=Zhang |first5=Hua |last6=Yang |first6=Dongyun |last7=Zhang |first7=Wu |last8=Shifa |first8=Belul Assefa |last9=Photiou |first9=Andrew |last10=Tralau-Stewart |first10=Cathy |last11=Castellano |first11=Leandro |last12=Green |first12=Andrew R. |last13=Coombes |first13=R. Charles |last14=Ellis |first14=Ian O. |last15=Ali |first15=Simak |last16=Lenz |first16=Heinz-Josef |last17=Stebbing |first17=Justin |title=Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer |journal=Nature Medicine |date=June 2011 |volume=17 |issue=6 |pages=715–719 |doi=10.1038/nm.2351 |pmid=21602804 |s2cid=5279914 }}{{psc|date=January 2022}}</ref><ref>{{cite journal |last1=Castellano |first1=Leandro |last2=Giamas |first2=Georgios |last3=Jacob |first3=Jimmy |last4=Coombes |first4=R. Charles |last5=Lucchesi |first5=Walter |last6=Thiruchelvam |first6=Paul |last7=Barton |first7=Geraint |last8=Jiao |first8=Long R. |last9=Wait |first9=Robin |last10=Waxman |first10=Jonathan |last11=Hannon |first11=Gregory J. |last12=Stebbing |first12=Justin |title=The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response |journal=Proceedings of the National Academy of Sciences |date=21 August 2009 |volume=106 |issue=37 |pages=15732–15737 |doi=10.1073/pnas.0906947106 |pmid=19706389 |pmc=2747188 |bibcode=2009PNAS..10615732C |doi-access=free }}{{psc|date=January 2022}}</ref><ref>{{cite journal |last1=Bower |first1=M. |last2=Nelson |first2=M. |last3=Young |first3=A.M. |last4=Thirlwell |first4=C. |last5=Newsom-Davis |first5=T. |last6=Mandalia |first6=S. |last7=Dhillon |first7=T. |last8=Holmes |first8=P. |last9=Gazzard |first9=B.G. |last10=Stebbing |first10=J. |title=Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma |journal=Journal of Clinical Oncology |date=1 August 2005 |volume=23 |issue=22 |pages=5224–5228 |doi=10.1200/JCO.2005.14.597 |pmid=16051964 |doi-access=free }}{{psc|date=January 2022}}</ref><ref>{{cite journal |last1=Stebbing |first1=Justin |last2=Gazzard |first2=Brian |last3=Douek |first3=Daniel C. |title=Where Does HIV Live? |journal=New England Journal of Medicine |date=29 April 2004 |volume=350 |issue=18 |pages=1872–1880 |doi=10.1056/NEJMra032395 |pmid=15115833 }}{{psc|date=January 2022}}</ref> He has undertaken extensive work on [[Biosimilar|biosimilars]],<ref>{{Cite web |title=Redirecting |url=https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(17)30434-5 |access-date=2024-01-07 |website=linkinghub.elsevier.com}}</ref> cheaper versions of expensive biologic drugs designed to democratise access to these around the world, now with long term outcomes data.<ref>{{Cite journal |last1=Stebbing |first1=Justin |last2=Baranau |first2=Yauheni |last3=Baryash |first3=Valery |last4=Moiseyenko |first4=Vladimir |last5=Boliukh |first5=Dmytro |last6=Antone |first6=Nicoleta |last7=Manikhas |first7=Alexey |last8=Chornobai |first8=Anatolii |last9=Park |first9=Taehong |last10=Baek |first10=Eric Hyungseok |last11=Lee |first11=Jaeyong |last12=Choi |first12=Jiin |last13=Kim |first13=Nahyun |last14=Ahn |first14=Keumyoung |last15=Lee |first15=Sang Joon |date=2023 |title=Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial |journal=Biodrugs |volume=37 |issue=3 |pages=433–440 |doi=10.1007/s40259-023-00582-w |issn=1173-8804 |pmid=36881323|pmc=10195725 }}</ref> In 2020, he was investigated by the [[General Medical Council]] over allegations that he failed to provide adequate care to eleven patients he had cared for between 2014 and 2017.<ref>{{Cite web |last=Naish |first=John |date=2022-09-12 |title=Why is regulator pursuing one of world's leading cancer specialists? |url=https://www.dailymail.co.uk/health/article-11204547/Why-medical-regulator-pursuing-one-worlds-leading-cancer-specialists.html |access-date=2024-05-18 |website=Mail Online}}</ref>


== COVID-19 research ==
== COVID-19 research ==
During the [[Covid-19]] in early 2020, Stebbing used artificial intelligence to identify [[baricitinib]] as a potential drug treatment.<ref>{{cite journal |last1=Richardson |first1=Peter |last2=Griffin |first2=Ivan |last3=Tucker |first3=Catherine |last4=Smith |first4=Dan |last5=Oechsle |first5=Olly |last6=Phelan |first6=Anne |last7=Rawling |first7=Michael |last8=Savory |first8=Edward |last9=Stebbing |first9=Justin |title=Baricitinib as potential treatment for 2019-nCoV acute respiratory disease |journal=The Lancet |date=15 February 2020 |volume=395 |issue=10223 |pages=e30–e31 |doi=10.1016/S0140-6736(20)30304-4 |pmid=32032529 |pmc=7137985 }}{{psc|date=January 2022}}</ref><ref>{{Cite web |title=Redirecting |url=https://linkinghub.elsevier.com/retrieve/pii/S1473-3099(20)30132-8 |access-date=2024-01-07 |website=linkinghub.elsevier.com}}</ref> He led studies that showed that the drug reduced mortality in COVID-19 hospitalised patients with pneumonia, which led to the drug being authorised by the [[Food and Drug Administration|US Food and Drug Administration]] in October 2020 as an [[Emergency Use Authorization]] at first in combination with remdesivir, then alone.<ref>{{Cite web |title=Olumiant EUA FAQs {{!}} FDA |url=https://www.fda.gov/media/143825 |access-date=2024-02-14 |website=www.fda.gov}}</ref> Much of this work is summarized by editorials he wrote in the [[The New England Journal of Medicine|New England Journal of Medicine]] and [[Lancet Respiratory Medicine]] which describe this further.<ref>{{Cite journal |last1=Stebbing |first1=Justin |last2=Lauschke |first2=Volker M. |date=2021-07-29 |title=JAK Inhibitors — More Than Just Glucocorticoids |journal=New England Journal of Medicine |language=en |volume=385 |issue=5 |pages=463–465 |doi=10.1056/NEJMe2108667 |issn=0028-4793 |pmc=8362590 |pmid=34320294}}</ref><ref>{{Cite journal |last1=Kalil |first1=Andre C |last2=Stebbing |first2=Justin |date=December 2021 |title=Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial |journal=The Lancet. Respiratory Medicine |volume=9 |issue=12 |pages=1349–1351 |doi=10.1016/S2213-2600(21)00358-1 |issn=2213-2600 |pmc=8409093 |pmid=34480862}}</ref> The book, ‘Witness to COVID, 2020’ <ref>{{Cite book|url=https://www.londonreviewbookshop.co.uk/stock/witness-to-covid-2020-the-diary-of-a-global-pandemic-justin-stebbing|isbn = 9781398112674|title = Witness to Covid: 2020 &#124; Justin Stebbing &#124; London Review Bookshop|date = 15 November 2021|last1 = Stebbing|first1 = Justin| publisher=Amberley }}</ref><ref>{{Cite book |url=https://www.londonreviewbookshop.co.uk/stock/witness-to-covid-2020-the-diary-of-a-global-pandemic-justin-stebbing |title=Witness to Covid: 2020 {{!}} Justin Stebbing {{!}} London Review Bookshop |date=2021-11-15 |isbn=978-1-3981-1267-4 |language=en-GB |last1=Stebbing |first1=Justin |publisher=Amberley }}</ref> was written by Justin Stebbing describing its discovery, trials, studies and approval,<ref>{{Cite book |title=Witness to Covid: 2020: The Diary of a Global Pandemic: Amazon.co.uk: Stebbing, Justin, Mukherjee, Siddhartha: 9781398112674: Books |id={{ASIN|1398112674|country=uk}} }}</ref> also highlighted in news outlets such as The [[The New York Times|New York Times]].<ref>{{Cite news |last=Metz |first=Cade |date=2020-04-30 |title=How A.I. Steered Doctors Toward a Possible Coronavirus Treatment |url=https://www.nytimes.com/2020/04/30/technology/coronavirus-treatment-benevolentai-baricitinib.html |access-date=2024-01-07 |work=The New York Times |language=en-US |issn=0362-4331}}</ref> In 2024 he was co-senior author on a paper in Nature Communications<ref>{{Cite journal |last1=Hammond |first1=Terese C. |last2=Purbhoo |first2=Marco A. |last3=Kadel |first3=Sapana |last4=Ritz |first4=Jerome |last5=Nikiforow |first5=Sarah |last6=Daley |first6=Heather |last7=Shaw |first7=Kit |last8=van Besien |first8=Koen |last9=Gomez-Arteaga |first9=Alexandra |last10=Stevens |first10=Don |last11=Ortuzar |first11=Waldo |last12=Michelet |first12=Xavier |last13=Smith |first13=Rachel |last14=Moskowitz |first14=Darrian |last15=Masakayan |first15=Reed |date=2024-02-06 |title=A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome |journal=Nature Communications |language=en |volume=15 |issue=1 |pages=974 |doi=10.1038/s41467-024-44905-z |pmid=38321023 |issn=2041-1723|pmc=10847411 |bibcode=2024NatCo..15..974H }}</ref> using [[Invariant natural killer T cell|invariant natural killer T cells]] as an 'off-the-shelf' therapy in ventilated patients with acute respiratory distress syndrome ([[Acute respiratory distress syndrome|ARDS]]), the first time these cells have been used in the clinic, as publicised.<ref>{{Cite news |last=Reporters |first=Telegraph |date=2024-02-07 |title=New cancer drug could improve prognosis for Covid patients |url=https://www.telegraph.co.uk/news/2024/02/07/new-cancer-drug-could-improve-prognosis-covid-patients/ |access-date=2024-02-14 |work=The Telegraph |language=en-GB |issn=0307-1235}}</ref>
During the [[Covid-19]] in early 2020, Stebbing used artificial intelligence to identify [[baricitinib]] as a potential drug treatment.<ref>{{cite journal |last1=Richardson |first1=Peter |last2=Griffin |first2=Ivan |last3=Tucker |first3=Catherine |last4=Smith |first4=Dan |last5=Oechsle |first5=Olly |last6=Phelan |first6=Anne |last7=Rawling |first7=Michael |last8=Savory |first8=Edward |last9=Stebbing |first9=Justin |title=Baricitinib as potential treatment for 2019-nCoV acute respiratory disease |journal=The Lancet |date=15 February 2020 |volume=395 |issue=10223 |pages=e30–e31 |doi=10.1016/S0140-6736(20)30304-4 |pmid=32032529 |pmc=7137985 }}{{psc|date=January 2022}}</ref><ref>{{Cite web |title=Redirecting |url=https://linkinghub.elsevier.com/retrieve/pii/S1473-3099(20)30132-8 |access-date=2024-01-07 |website=linkinghub.elsevier.com}}</ref> He led studies that showed that the drug reduced mortality in COVID-19 hospitalised patients with pneumonia, which led to the drug being authorised by the [[Food and Drug Administration|US Food and Drug Administration]] in October 2020 as an [[Emergency Use Authorization]] at first in combination with remdesivir, then alone.<ref>{{Cite web |title=Olumiant EUA FAQs {{!}} FDA |url=https://www.fda.gov/media/143825 |access-date=2024-02-14 |website=www.fda.gov}}</ref> Much of this work is summarized by editorials he wrote in the [[The New England Journal of Medicine|New England Journal of Medicine]] and [[Lancet Respiratory Medicine]] which describe this further.<ref>{{Cite journal |last1=Stebbing |first1=Justin |last2=Lauschke |first2=Volker M. |date=2021-07-29 |title=JAK Inhibitors — More Than Just Glucocorticoids |journal=New England Journal of Medicine |language=en |volume=385 |issue=5 |pages=463–465 |doi=10.1056/NEJMe2108667 |issn=0028-4793 |pmc=8362590 |pmid=34320294}}</ref><ref>{{Cite journal |last1=Kalil |first1=Andre C |last2=Stebbing |first2=Justin |date=December 2021 |title=Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial |journal=The Lancet. Respiratory Medicine |volume=9 |issue=12 |pages=1349–1351 |doi=10.1016/S2213-2600(21)00358-1 |issn=2213-2600 |pmc=8409093 |pmid=34480862}}</ref> The book, ‘Witness to COVID, 2020’ <ref>{{Cite book|url=https://www.londonreviewbookshop.co.uk/stock/witness-to-covid-2020-the-diary-of-a-global-pandemic-justin-stebbing|isbn = 9781398112674|title = Witness to Covid: 2020 &#124; Justin Stebbing &#124; London Review Bookshop|date = 15 November 2021|last1 = Stebbing|first1 = Justin| publisher=Amberley }}</ref><ref>{{Cite book |url=https://www.londonreviewbookshop.co.uk/stock/witness-to-covid-2020-the-diary-of-a-global-pandemic-justin-stebbing |title=Witness to Covid: 2020 {{!}} Justin Stebbing {{!}} London Review Bookshop |date=2021-11-15 |isbn=978-1-3981-1267-4 |language=en-GB |last1=Stebbing |first1=Justin |publisher=Amberley }}</ref> was written by Justin Stebbing describing its discovery, trials, studies and approval,<ref>{{Cite book |title=Witness to Covid: 2020: The Diary of a Global Pandemic: Amazon.co.uk: Stebbing, Justin, Mukherjee, Siddhartha: 9781398112674: Books |id={{ASIN|1398112674|country=uk}} }}</ref> also highlighted in news outlets such as The [[The New York Times|New York Times]].<ref>{{Cite news |last=Metz |first=Cade |date=2020-04-30 |title=How A.I. Steered Doctors Toward a Possible Coronavirus Treatment |url=https://www.nytimes.com/2020/04/30/technology/coronavirus-treatment-benevolentai-baricitinib.html |access-date=2024-01-07 |work=The New York Times |language=en-US |issn=0362-4331}}</ref> In 2024 he was co-senior author on a paper in Nature Communications<ref>{{Cite journal |last1=Hammond |first1=Terese C. |last2=Purbhoo |first2=Marco A. |last3=Kadel |first3=Sapana |last4=Ritz |first4=Jerome |last5=Nikiforow |first5=Sarah |last6=Daley |first6=Heather |last7=Shaw |first7=Kit |last8=van Besien |first8=Koen |last9=Gomez-Arteaga |first9=Alexandra |last10=Stevens |first10=Don |last11=Ortuzar |first11=Waldo |last12=Michelet |first12=Xavier |last13=Smith |first13=Rachel |last14=Moskowitz |first14=Darrian |last15=Masakayan |first15=Reed |date=2024-02-06 |title=A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome |journal=Nature Communications |language=en |volume=15 |issue=1 |pages=974 |doi=10.1038/s41467-024-44905-z |pmid=38321023 |issn=2041-1723|pmc=10847411 |bibcode=2024NatCo..15..974H }}</ref> using [[Invariant natural killer T cell|invariant natural killer T cells]] as an 'off-the-shelf' therapy in ventilated patients with acute respiratory distress syndrome ([[Acute respiratory distress syndrome|ARDS]]), the first time these cells have been used in the clinic, as publicised.<ref>{{Cite news |last=Reporters |first=Telegraph |date=2024-02-07 |title=New cancer drug could improve prognosis for Covid patients |url=https://www.telegraph.co.uk/news/2024/02/07/new-cancer-drug-could-improve-prognosis-covid-patients/ |access-date=2024-02-14 |work=The Telegraph |language=en-GB |issn=0307-1235}}</ref>

== Misconduct case ==
In 2020, Professor Justin Stebbing was investigated by the [[General Medical Council]] over allegations that he failed to provide adequate care to eleven patients he had cared for between 2014 and 2017.<ref>{{Cite journal |last=Dyer |first=Clare |date=2020-09-15 |title=Leading oncologist faces GMC allegations of inappropriate treatment of dying patients |url=https://www.bmj.com/lookup/doi/10.1136/bmj.m3594 |journal=BMJ |language=en |pages=m3594 |doi=10.1136/bmj.m3594 |issn=1756-1833}}</ref><ref>{{Cite web |title=Leading Oncologist Guilty of Providing Inappropriate Treatment: MPTS |url=https://www.medscape.co.uk/viewarticle/leading-oncologist-guilty-misconduct-mpts-2021a1001ygw |access-date=2022-05-25 |website=Medscape UK |language=en}}</ref> The case focused on whether Stebbing had prescribed inappropriate courses of treatment in patients whose cancers were too advanced to benefit from the treatment.<ref>https://blogs.bmj.com/medical-ethics/2022/11/13/saviour-or-sinner-why-the-case-of-justin-stebbing-matters/</ref> Following a Medical Practitioners Tribunal Service [[Medical malpractice|misconduct]] hearing, the GMG suspended Stebbing from the UK medical register for nine months in 2022.<ref>{{Cite journal |last=Dyer |first=Clare |date=2021-12-21 |title=Oncologist with “cavalier attitude” to treatment is suspended for nine months after patients defend his practice |url=https://www.bmj.com/lookup/doi/10.1136/bmj.n3130 |journal=BMJ |language=en |pages=n3130 |doi=10.1136/bmj.n3130 |issn=1756-1833}}</ref>


== Other work ==
== Other work ==
Stebbing has worked on neurological therapies for patients with unmet medical needs who are treatment resistant or unresponsive to other existing medications.<ref>{{Cite press release |last=Corp |first=Equilibre Biopharmaceuticals |title=Equilibre Biopharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of EQU-001 (NCT05063877) for Safety, Tolerability and Preliminary Efficacy as Adjunctive Therapy for Focal Seizures in Adults with Epilepsy |url=https://www.prnewswire.com/news-releases/equilibre-biopharmaceuticals-announces-positive-topline-results-from-phase-2-clinical-trial-of-equ-001-nct05063877-for-safety-tolerability-and-preliminary-efficacy-as-adjunctive-therapy-for-focal-seizures-in-adults-with-epileps-301732789.html |access-date=2024-01-07 |website=www.prnewswire.com |language=en}}</ref> He has combined his medical career with investing, and he has worked with [[Atticus Capital]], [[Lansdowne Partners]], [[Vitruvian Partners]] and Chaired the Board of [[BB Healthcare Trust]].<ref>{{Cite web |date=2018-02-14 |title=BB Healthcare Trust delivers as it comfortably beats its benchmark |url=https://www.proactiveinvestors.co.uk/companies/news/191621/bb-healthcare-trust-delivers-as-it-comfortably-beats-its-benchmark-191621.html |access-date=2024-01-07 |website=Proactiveinvestors UK |language=en}}</ref> He is actively engaged with a number of companies, is senior oncology advisor to [https://www.clinicalink.com/ Clinical ink]<ref>{{Cite web |title=Justin Stebbing, PhD, M.D. {{!}} Expert Advisor |url=https://www.clinicalink.com/company/leadership/justin-stebbing/ |access-date=2024-01-07 |website=Clinical ink |language=en-US}}</ref> and chairs the [https://www.zephyrai.bio/team ZephyrAI] scientific advisory board.<ref>{{Cite web |date=2022-12-05 |title=Zephyr AI Announces Formation of Scientific and Medical Advisory Board |url=https://www.businesswire.com/news/home/20221205005251/en/Zephyr-AI-Announces-Formation-of-Scientific-and-Medical-Advisory-Board |access-date=2024-01-07 |website=www.businesswire.com |language=en}}</ref> He is senior VP of clinical strategy and innovation<ref>{{Cite web |title=Our Company |url=https://gravitoncorp.com/company/ |access-date=2024-02-14 |website=gravitoncorp.com}}</ref> at [https://gravitoncorp.com/ Graviton Biosciences] focusing on new treatments for fibrosis, inflammation and metabolism based on selective targeting of [[ROCK2]].
Stebbing has worked on neurological therapies for patients with unmet medical needs who are treatment resistant or unresponsive to other existing medications.<ref>{{Cite press release |last=Corp |first=Equilibre Biopharmaceuticals |title=Equilibre Biopharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of EQU-001 (NCT05063877) for Safety, Tolerability and Preliminary Efficacy as Adjunctive Therapy for Focal Seizures in Adults with Epilepsy |url=https://www.prnewswire.com/news-releases/equilibre-biopharmaceuticals-announces-positive-topline-results-from-phase-2-clinical-trial-of-equ-001-nct05063877-for-safety-tolerability-and-preliminary-efficacy-as-adjunctive-therapy-for-focal-seizures-in-adults-with-epileps-301732789.html |access-date=2024-01-07 |website=www.prnewswire.com |language=en}}</ref> He has combined his medical career with investing, and he has worked with [[Atticus Capital]], [[Lansdowne Partners]], [[Vitruvian Partners]] and Chaired the Board of [[BB Healthcare Trust]].<ref>{{Cite web |date=2018-02-14 |title=BB Healthcare Trust delivers as it comfortably beats its benchmark |url=https://www.proactiveinvestors.co.uk/companies/news/191621/bb-healthcare-trust-delivers-as-it-comfortably-beats-its-benchmark-191621.html |access-date=2024-01-07 |website=Proactiveinvestors UK |language=en}}</ref> He is actively engaged with a number of companies, is senior oncology advisor to [https://www.clinicalink.com/ Clinical ink]<ref>{{Cite web |title=Justin Stebbing, PhD, M.D. {{!}} Expert Advisor |url=https://www.clinicalink.com/company/leadership/justin-stebbing/ |access-date=2024-01-07 |website=Clinical ink |language=en-US}}</ref> and chairs the [https://www.zephyrai.bio/team ZephyrAI] scientific advisory board.<ref>{{Cite web |date=2022-12-05 |title=Zephyr AI Announces Formation of Scientific and Medical Advisory Board |url=https://www.businesswire.com/news/home/20221205005251/en/Zephyr-AI-Announces-Formation-of-Scientific-and-Medical-Advisory-Board |access-date=2024-01-07 |website=www.businesswire.com |language=en}}</ref> Since 2024 he has served on the Board of Directors for [https://etira.life/ Etira Therapeutics]<ref>{{Cite web |title=Leadership |url=https://etira.life/leadership/ |access-date=2024-05-18 |website=etira |language=en-US}}</ref> and [https://www.portagebiotech.com/ Portage]<ref>{{Cite web |title=about us |url=https://www.portagebiotech.com/about-us/ |access-date=2024-05-18 |website=Portage Biotech |language=en-US}}</ref>. He is senior VP of clinical strategy and innovation<ref>{{Cite web |title=Our Company |url=https://gravitoncorp.com/company/ |access-date=2024-02-14 |website=gravitoncorp.com}}</ref> at [https://gravitoncorp.com/ Graviton Biosciences] focusing on new treatments for fibrosis, inflammation and metabolism based on selective targeting of [[ROCK2]].
==References==
==References==
{{Reflist}}
{{Reflist}}

Revision as of 07:03, 18 May 2024

Justin Stebbing

Justin Stebbing is a British oncology doctor, cancer researcher and academic journal editor. He is a Professor of Biomedical Sciences at Anglia Ruskin University[1] and practices with the private sector Phoenix Hospital Group in London to provide medical services to patients for the management of cancer, in person and remotely.[2]

He specialises in a range of solid malignancies (breast, GI, lung, others) including difficult cases with few conventional options and has published over 700 papers, the majority regarding new therapeutic and translational approaches including use of immunotherapies in clinical trials.[3]

He is Editor-in-Chief of the journal Oncogene.[4] He is also a visiting Professor of Cancer Medicine and Oncology at Imperial College, London [5]

Early life and education

He graduated with a first class degree from Trinity College, Oxford. After completion of junior doctor positions in Oxford, he trained on the residency programme at The Johns Hopkins Hospital on the Longcope team in the US, returning to London to continue his career in oncology at The Royal Marsden and then St Bartholomew's Hospitals. His original PhD research investigated the interplay between the immune system and cancer including the role of viruses here.[6][7] In 2007 he was appointed a senior lecturer, and then in 2009 a full professor, at Imperial College London.[8] In 2011, the National Institute for Health and Care Research (NIHR) awarded Justin Stebbing its first Translational Professorship in Oncology, working on overcoming treatment resistance and new targeted precision medicine approaches.[9]

Cancer research

Stebbing has published over 700 peer-reviewed papers in academic journals[10] and has an h-index of 89 according to Google Scholar.[11] He is Editor-in-Chief of the journal Oncogene[12] a Fellow of the Royal College of Physicians[13] the American Society for Clinical Investigation[14] and the Royal College of Pathologists.[15] The charity Action Against Cancer was set up to support Justin's work which concentrates on drug development and has the ambitious goal of developing cures.[16] In cancer, some of his most cited papers include the discovery of the role of the oncogene LMTK3 across malignancies, the network of microRNAs induced by the estrogen receptor, and extensive work on HIV and AIDS cancers.[17][18][19][20] He has undertaken extensive work on biosimilars,[21] cheaper versions of expensive biologic drugs designed to democratise access to these around the world, now with long term outcomes data.[22] In 2020, he was investigated by the General Medical Council over allegations that he failed to provide adequate care to eleven patients he had cared for between 2014 and 2017.[23]

COVID-19 research

During the Covid-19 in early 2020, Stebbing used artificial intelligence to identify baricitinib as a potential drug treatment.[24][25] He led studies that showed that the drug reduced mortality in COVID-19 hospitalised patients with pneumonia, which led to the drug being authorised by the US Food and Drug Administration in October 2020 as an Emergency Use Authorization at first in combination with remdesivir, then alone.[26] Much of this work is summarized by editorials he wrote in the New England Journal of Medicine and Lancet Respiratory Medicine which describe this further.[27][28] The book, ‘Witness to COVID, 2020’ [29][30] was written by Justin Stebbing describing its discovery, trials, studies and approval,[31] also highlighted in news outlets such as The New York Times.[32] In 2024 he was co-senior author on a paper in Nature Communications[33] using invariant natural killer T cells as an 'off-the-shelf' therapy in ventilated patients with acute respiratory distress syndrome (ARDS), the first time these cells have been used in the clinic, as publicised.[34]

Other work

Stebbing has worked on neurological therapies for patients with unmet medical needs who are treatment resistant or unresponsive to other existing medications.[35] He has combined his medical career with investing, and he has worked with Atticus Capital, Lansdowne Partners, Vitruvian Partners and Chaired the Board of BB Healthcare Trust.[36] He is actively engaged with a number of companies, is senior oncology advisor to Clinical ink[37] and chairs the ZephyrAI scientific advisory board.[38] Since 2024 he has served on the Board of Directors for Etira Therapeutics[39] and Portage[40]. He is senior VP of clinical strategy and innovation[41] at Graviton Biosciences focusing on new treatments for fibrosis, inflammation and metabolism based on selective targeting of ROCK2.

References

  1. ^ "Professor Justin Stebbing - ARU". aru.ac.uk. Retrieved 2022-11-30.
  2. ^ "Professor Justin Stebbing". Phoenix Hospital Group. Retrieved 2022-10-29.
  3. ^ Stebbing, Justin (2024-05-16). "Unlocking the body's defences: understanding immunotherapy". The Conversation. Retrieved 2024-05-18.
  4. ^ "About the Editors | Oncogene". www.nature.com. Retrieved 2022-10-29.
  5. ^ "Home - Professor Justin Stebbing". www.imperial.ac.uk. Retrieved 2022-10-29.
  6. ^ Stebbing, Justin; Gazzard, Brian; Douek, Daniel C. (2004-04-29). "Where Does HIV Live?". New England Journal of Medicine. 350 (18): 1872–1880. doi:10.1056/NEJMra032395. ISSN 0028-4793. PMID 15115833.
  7. ^ "Redirecting". linkinghub.elsevier.com. Retrieved 2024-01-07.
  8. ^ "PWP Messages".
  9. ^ "Current NIHR Research Professors". www.nihr.ac.uk. Retrieved 2024-01-07.
  10. ^ "stebbing j - Search Results - PubMed". PubMed. Retrieved 2024-01-07.
  11. ^ "Justin Stebbing". scholar.google.com. Retrieved 2024-01-07.
  12. ^ "About the Editors". Oncogene.
  13. ^ "Home - Professor Justin Stebbing". www.imperial.ac.uk. Retrieved 2024-01-07.
  14. ^ "The American Society for Clinical Investigation".
  15. ^ "Honours and Memberships - Professor Justin Stebbing". www.imperial.ac.uk. Retrieved 2024-01-07.
  16. ^ "Home | Action Against Cancer". www.aacancer.org. Retrieved 28 March 2023.
  17. ^ Giamas, Georgios; Filipović, Aleksandra; Jacob, Jimmy; Messier, Walter; Zhang, Hua; Yang, Dongyun; Zhang, Wu; Shifa, Belul Assefa; Photiou, Andrew; Tralau-Stewart, Cathy; Castellano, Leandro; Green, Andrew R.; Coombes, R. Charles; Ellis, Ian O.; Ali, Simak; Lenz, Heinz-Josef; Stebbing, Justin (June 2011). "Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer". Nature Medicine. 17 (6): 715–719. doi:10.1038/nm.2351. PMID 21602804. S2CID 5279914.[non-primary source needed]
  18. ^ Castellano, Leandro; Giamas, Georgios; Jacob, Jimmy; Coombes, R. Charles; Lucchesi, Walter; Thiruchelvam, Paul; Barton, Geraint; Jiao, Long R.; Wait, Robin; Waxman, Jonathan; Hannon, Gregory J.; Stebbing, Justin (21 August 2009). "The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response". Proceedings of the National Academy of Sciences. 106 (37): 15732–15737. Bibcode:2009PNAS..10615732C. doi:10.1073/pnas.0906947106. PMC 2747188. PMID 19706389.[non-primary source needed]
  19. ^ Bower, M.; Nelson, M.; Young, A.M.; Thirlwell, C.; Newsom-Davis, T.; Mandalia, S.; Dhillon, T.; Holmes, P.; Gazzard, B.G.; Stebbing, J. (1 August 2005). "Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma". Journal of Clinical Oncology. 23 (22): 5224–5228. doi:10.1200/JCO.2005.14.597. PMID 16051964.[non-primary source needed]
  20. ^ Stebbing, Justin; Gazzard, Brian; Douek, Daniel C. (29 April 2004). "Where Does HIV Live?". New England Journal of Medicine. 350 (18): 1872–1880. doi:10.1056/NEJMra032395. PMID 15115833.[non-primary source needed]
  21. ^ "Redirecting". linkinghub.elsevier.com. Retrieved 2024-01-07.
  22. ^ Stebbing, Justin; Baranau, Yauheni; Baryash, Valery; Moiseyenko, Vladimir; Boliukh, Dmytro; Antone, Nicoleta; Manikhas, Alexey; Chornobai, Anatolii; Park, Taehong; Baek, Eric Hyungseok; Lee, Jaeyong; Choi, Jiin; Kim, Nahyun; Ahn, Keumyoung; Lee, Sang Joon (2023). "Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial". Biodrugs. 37 (3): 433–440. doi:10.1007/s40259-023-00582-w. ISSN 1173-8804. PMC 10195725. PMID 36881323.
  23. ^ Naish, John (2022-09-12). "Why is regulator pursuing one of world's leading cancer specialists?". Mail Online. Retrieved 2024-05-18.
  24. ^ Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Rawling, Michael; Savory, Edward; Stebbing, Justin (15 February 2020). "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease". The Lancet. 395 (10223): e30–e31. doi:10.1016/S0140-6736(20)30304-4. PMC 7137985. PMID 32032529.[non-primary source needed]
  25. ^ "Redirecting". linkinghub.elsevier.com. Retrieved 2024-01-07.
  26. ^ "Olumiant EUA FAQs | FDA". www.fda.gov. Retrieved 2024-02-14.
  27. ^ Stebbing, Justin; Lauschke, Volker M. (2021-07-29). "JAK Inhibitors — More Than Just Glucocorticoids". New England Journal of Medicine. 385 (5): 463–465. doi:10.1056/NEJMe2108667. ISSN 0028-4793. PMC 8362590. PMID 34320294.
  28. ^ Kalil, Andre C; Stebbing, Justin (December 2021). "Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial". The Lancet. Respiratory Medicine. 9 (12): 1349–1351. doi:10.1016/S2213-2600(21)00358-1. ISSN 2213-2600. PMC 8409093. PMID 34480862.
  29. ^ Stebbing, Justin (15 November 2021). Witness to Covid: 2020 | Justin Stebbing | London Review Bookshop. Amberley. ISBN 9781398112674.
  30. ^ Stebbing, Justin (2021-11-15). Witness to Covid: 2020 | Justin Stebbing | London Review Bookshop. Amberley. ISBN 978-1-3981-1267-4.
  31. ^ Witness to Covid: 2020: The Diary of a Global Pandemic: Amazon.co.uk: Stebbing, Justin, Mukherjee, Siddhartha: 9781398112674: Books. ASIN 1398112674.
  32. ^ Metz, Cade (2020-04-30). "How A.I. Steered Doctors Toward a Possible Coronavirus Treatment". The New York Times. ISSN 0362-4331. Retrieved 2024-01-07.
  33. ^ Hammond, Terese C.; Purbhoo, Marco A.; Kadel, Sapana; Ritz, Jerome; Nikiforow, Sarah; Daley, Heather; Shaw, Kit; van Besien, Koen; Gomez-Arteaga, Alexandra; Stevens, Don; Ortuzar, Waldo; Michelet, Xavier; Smith, Rachel; Moskowitz, Darrian; Masakayan, Reed (2024-02-06). "A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome". Nature Communications. 15 (1): 974. Bibcode:2024NatCo..15..974H. doi:10.1038/s41467-024-44905-z. ISSN 2041-1723. PMC 10847411. PMID 38321023.
  34. ^ Reporters, Telegraph (2024-02-07). "New cancer drug could improve prognosis for Covid patients". The Telegraph. ISSN 0307-1235. Retrieved 2024-02-14.
  35. ^ Corp, Equilibre Biopharmaceuticals. "Equilibre Biopharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of EQU-001 (NCT05063877) for Safety, Tolerability and Preliminary Efficacy as Adjunctive Therapy for Focal Seizures in Adults with Epilepsy". www.prnewswire.com (Press release). Retrieved 2024-01-07.
  36. ^ "BB Healthcare Trust delivers as it comfortably beats its benchmark". Proactiveinvestors UK. 2018-02-14. Retrieved 2024-01-07.
  37. ^ "Justin Stebbing, PhD, M.D. | Expert Advisor". Clinical ink. Retrieved 2024-01-07.
  38. ^ "Zephyr AI Announces Formation of Scientific and Medical Advisory Board". www.businesswire.com. 2022-12-05. Retrieved 2024-01-07.
  39. ^ "Leadership". etira. Retrieved 2024-05-18.
  40. ^ "about us". Portage Biotech. Retrieved 2024-05-18.
  41. ^ "Our Company". gravitoncorp.com. Retrieved 2024-02-14.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Justin_Stebbing&oldid=1224409881"